p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

Inclusion Criteria: * Patients must have histologically confirmed primary progressive, recurrent or refractory CNS tumors with no known curative therapies limited to high grade glioma, such as glioblastoma multiforme, medulloblastoma, primitive neuroectodermal tumor, atypical teratoid/rhabdoid tumor, anaplastic astrocytoma, high-grade astrocytoma not otherwise specified (NOS), anaplastic oligodendroglioma, or choroid plexus carcinoma; or diffuse intrinsic pontine glioma; the requirements for histological verification are waived for diffuse intrinsic pontine glioma * Patients must not have received myelosuppressive chemotherapy or immunotherapy within 3 weeks of registration (6 weeks if prior nitrosourea) * Patients must have received their last dose of biologic agent \>= 7 days prior to study registration * Steroid dose should be stable or decreasing for at least 1 week prior to registration * If prior therapy was monoclonal antibody, 30 days or 3 half-lives must have elapsed (whichever is longer), prior to registration * Patient must be off all colony stimulating factors \> 1 week prior to registration (filgrastim \[GCSF\], sargramostim \[GM CSF\], erythropoietin) * Any craniospinal irradiation must have taken place \>= 3 months prior to registration \>= 8 weeks for local irradiation to primary tumor; \>= 2 weeks prior to study entry for focal irradiation for symptomatic metastatic sites * Karnofsky performance scale (KPS) (for \> 16 years \[yrs\] of age) or Lansky performa…